Pharmacological Results
We studied the pharmacokinetics of ropivacaine after a continuous SAPB injection in 88 patients aged 18-70 years with BMI 18-30 kg/m2 (44 patients in each group). All expected blood samples were collected. The peak total plasma concentrations of ropivacaine were 2.93 μg·mL−1 in Group H and 2.01 μg·mL−1 in Group L 48 hours after injection (Figure 2). The maximum total plasma level of ropivacaine was still well below the theoretical toxicity threshold of 3.40 μg·mL−1[18].